Rare Disease Focus Retrophin concentrates on kidney and liver rare diseases with high unmet need, presenting an opportunity to cross-sell specialized therapies and expand patient access programs to nephrology and hepatology specialists.

Diversified Revenue With four commercial products already generating revenue, there is potential to upsell or bundle services and support for clinicians and hospitals managing patients on Chenodal, Cholbam, and tiopronin therapies.

Late-Stage Pipeline A robust late-stage pipeline including sparsentan for FSGS and IgAN offers collaboration avenues for co-development, strategic partnerships, and joint payer discussions to demonstrate value in high-need markets.

Clinical Partnerships History of advocacy and government research collaborations suggests opportunities to co-create patient access programs, real-world evidence studies, and policy-driven initiatives that can drive uptake and visibility.

Growth Channels Mid-sized biotech profile with global ambitions indicates potential for regional partnerships, contract manufacturing, and distribution agreements to scale commercialization in nephrology and hepatology segments.